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To characterize the epidemiology and prognostic factors of invasive fusariosis in hematopoietic stem cell
transplant (HSCT) recipients, the records of HSCT recipients from 9 hospitals (7 in Brazil and 2 in the United
States) were retrospectively reviewed. Sixty-one cases were identified: 54 in allogeneic HSCT recipients and 7
in autologous HSCT recipients. The incidence of fusariosis among allogeneic HSCT recipients varied between
a range of 4.21–5.0 cases per 1000 in human leukocyte antigen (HLA)—matched related transplant recipients
to 20.19 cases per 1000 in HLA-mismatched transplant recipients. The median time period between trans-
plantation and diagnosis of fusariosis was 48 days. Among allogeneic HSCT recipients, a trimodal distribution
was observed: a first peak before engraftment, a second peak at a median of 62 days after transplantation,
and a third peak 11 year after transplantation. The actuarial survival was 13% (median, 13 days). Persistent
neutropenia was the single prognostic factor for death identified by multivariate analysis.
The epidemiology of fungal infections in hematopoietic
stem cell transplant (HSCT) recipients has changed in
the past decade, with a decrease in infections caused
by Candida species after the introduction of triazole
prophylaxis and an increase in invasive aspergillosis [1]
and other mold infections [2]. Among the latter, Fu-
sarium infections have been reported with increasing
frequency. In patients with hematological malignancies,
fusariosis is associated with a very poor prognosis [3].
However, the clinicopathologic features and outcome
of HSCT recipients with invasive fusariosis have not
been previously described. In this study, we describe
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the clinical features and prognostic outcome factors of
61 patients with fusariosis after HSCT.
PATIENTS AND METHODS
All patients with invasive fusariosis after HSCT who
were cared for at 2 US centers and 7 Brazilian centers
from 1985 through 2001 were identified by a review of
the clinical records of patients with invasive fungal in-
fections. A standardized case report form containing
the pertinent clinical information was completed by all
investigators and sent to one of us (M.N.) for analysis.
The study was approved by the ethical review com-
mittees of the participating institutions.
The diagnosis of fusariosis was classified as proven,
probable, or possible, according to previously estab-
lished criteria [4]. Briefly, proven fusariosis was defined
as the growth of Fusarium species in cultures of blood
or cultures of samples obtained from other sterile sites
in patients with clinical signs of infection or the dem-
onstration of hyphae in tissue together with recovery
of Fusarium species from the same tissue. Probable fu-
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sariosis was defined as the growth of Fusarium species from
respiratory tract secretions obtained from patients with clinical
signs of infection compatible with fusariosis in the absence of
other pathogens. Patients with positive cultures of skin lesions
(e.g., cellulitis, nodules) without histopathologic demonstration
of hyphae were also included in this category. Cases of possible
infection were excluded.
The incidence of fusariosis was calculated by using the num-
ber of HSCTs performed during the same period as a denom-
inator. Survival was defined as the time between the date of
diagnosis of fusariosis and death or last follow-up. The date of
diagnosis was defined as the day of the first culture positive
for Fusarium. If the diagnosis of fusariosis was made post-
mortem, the date of death was considered the date of diagnosis.
Persistent neutropenia was defined as an absolute neutrophil
count of !500 neutrophils/mm3 for 17 days. Acute graft-versus-
host disease (aGVHD) was classified in grades 1 to 4, and
chronic graft-versus-host disease (cGVHD) was classified as
localized or extensive, as defined previously [5, 6]. Disseminated
infection was defined as involvement of 2 noncontiguous
organs. Data were censored after 90 days.
Prognostic factors for fusariosis were assessed by univariate
and multivariate Cox proportional-hazard regression analyses,
with survival as the end point variable. Variables with P ! .10
in the univariate analysis were included in the multivariate
analysis model. was considered statistically significant.P .05
The following variables were analyzed: age, sex, type and status
of underlying disease, type of HSCT, presence of neutropenia
(!500 neutrophils/mm3), presence and grade of aGVHD and
cGVHD, use of corticosteroids, concomitant infections, extent
of fusarial infection (localized or disseminated), antifungal ther-
apy, use of granulocyte colony-stimulating factor (G-CSF) or
granulocyte-macrophage colony-stimulating factor, and WBC
transfusions.
RESULTS
Sixty-one HSCT recipients (54 allogeneic, 7 autologous) with
fusariosis were identified. The donor source for the 54 allo-
geneic HSCT patients was an HLA-compatible related donor
(MRD) for 29 (48%) of the patients, an HLA-compatible un-
related donor (MUD) for 19 (31%) of the patients, and an
HLA-mismatched related donor (MMRD) for 6 (10%) of the
patients. The stem cell source for the 54 allogeneic HSCT re-
cipients was bone marrow in 51 patients and peripheral blood
in 3, whereas 6 of the 7 autologous stem cell transplant (AuSCT)
recipients received a bone marrow stem cell product.
The diagnosis of fusariosis was established on the basis of
specimens obtained from various organs: blood (in 28% of
cases), skin (in 20%), blood and skin (in 16%), lungs and
sinuses (in 11% each), and others (in 14%). Fifty-six patients
(92%) had proven and 5 (8%) had probable fusariosis. Dis-
seminated infection with metastatic skin lesions was the most
frequent clinical presentation, occurring in 46 (75%) of pa-
tients, followed by fungemia alone (11%) and sinusitis and
pneumonia (4 patients each).
The overall incidence of fusariosis was 5.97 cases per 1000
transplants and varied among the different institutions (range,
5.00–11.33 cases per 1000 transplants), but not between the 2
countries (6.18 cases per 1000 transplants in Brazil vs. 5.89
cases per 1000 transplants in the United States). The incidence
differed according to the type of allogeneic HSCT: 4.21–5.0
cases per 1000 MRDs, 2.28 per 1000 HLA-compatible MUDs,
and 20.19 per 1000 MMRDs. An incidence of 1.4 –2.0 per 1000
AuSCTs was observed.
The majority of allogeneic HSCT recipients had leukemia
and were not in complete remission at the time of transplan-
tation. At diagnosis of fusariosis, 46% of patients were neu-
tropenic and most had aGVHD or cGVHD (table 1). Patients
from Brazil differed from American patients. They were
younger (median age, 22 years vs. 41 years), more likely to
have chronic myeloid leukemia or aplastic anemia, more likely
to have received an MRD transplant, and more likely to be
neutropenic at the time of diagnosis of fusariosis. On the other
hand, patients from the United States were more likely to have
received a diagnosis of acute myeloid leukemia and more likely
to have received a non-MRD transplant (i.e, an AuSCT or a
transplant from an MUD or MMRD).
Disseminated infection was most commonly observed during
the first 100 days after transplantation (table 2) and was as-
sociated with neutropenia (OR, 10.11; 95% CI, 1.03–50.14;
). The median time period between stem cell trans-Pp .005
plantation and diagnosis of fusariosis was 64 days (range, 1–
1017 days) with a trimodal distribution: a first peak (early
fusariosis) before engraftment (median, 16 days), a second peak
(late fusariosis) between day 61 and day 80 (median, 64 days),
and a third peak (very late fusariosis) after day 360 (figure 1).
All 8 allogeneic HSCT recipients in the latter group had ade-
quate neutrophil counts at diagnosis of fusariosis. Five had
received an MUD (4 patients) or MMRD (1 patient) transplant.
Among the 4 MUD transplant recipients, 3 received a second
allogeneic HSCT provided for treatment of their relapsing acute
leukemia and developed fusariosis after engraftment, whereas
the remaining patient was receiving therapy for extensive c-
GVHD. One MMRD transplant recipient and 3 MRD trans-
plant recipients were also receiving treatment for extensive
cGVHD. As shown in figure 2, a greater number of cases was
observed during the late 1990s, especially cases occurring 130
days after transplantation.
Among the 8 AuSCT recipients, the median time between
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Table 1. Demographic and clinical characteristics of 61 hematopoietic stem cell transplant
(HSCT) recipients with fusariosis, by country of origin.
Characteristic
United States
(n p 42)
Brazil
(n p 19)
Total
(n p 61)
No. of male subjects/no. of female subjects 20/22 14/5 34/27
Age at diagnosis of fusariosis, median years (range)a 41 (2–67) 22 (7–48) 34 (2–67)
Underlying condition
Acute myeloid leukemiaa 17 (40) 2 (11) 19 (31)
Chronic myeloid leukemiaa 6 (14) 8 (42) 14 (23)
Acute lymphoid leukemia 6 (14) 3 (16) 9 (15)
Aplastic anemiaa 1 (2.4) 4 (21) 5 (8)
Myelodysplastic syndrome 1 (2.4) 2 (10.5) 3 (5)
Non-Hodgkin lymphoma 3 (7) 0 3 (5)
Multiple myeloma 2 (5) 0 2 (3)
Chronic lymphocytic leukemia 2 (5) 0 2 (3)
Solid tumor 2 (5) 0 2 (3)
Hodgkin disease 1 (2.4) 0 1 (2)
Genetic disorder 1 (2.4) 0 1 (2)
Underlying condition not in complete remissionb 34/39 (87) 10/15 (67) 44/54 (81)
Type of stem cell transplant
Allogeneic, HLA-compatible, related donora 15 (36) 14 (74) 29 (48)
Allogeneic, mismatched, related donor 5 (12) 1 (5) 6 (10)
Allogeneic, HLA-compatible, unrelated donor 15 (36) 4 (21) 19 (31)
Autologous 7 (17) 0 7 (11)
Characteristics at diagnosis of fusariosis in 54
allogeneic HSCT recipients
Neutropeniaa 11/35 (31) 14/19 (74) 25 (41)
Acute GVHD 16/35 (46) 6/19 (32) 31/54 (57)
Grade 1 0 1 1
Grade 2 4 2 11
Grade 3 8 0 12
Grade 4 4 3 7
Chronic GVHD 10/35 (29) 2 (11) 11/54 (20)
Localized 1 1 2
Extensive 9 1 9
Use of corticosteroids 21 (50) 11 (58) 32 (52)
NOTE. Data are expressed as n (%) unless otherwise indicated. GVHD, graft-versus-host disease.
a .P ! .05
b For patients with chronic myeloid leukemia, accelerated phase, or blast crisis.
transplantation and diagnosis of fusariosis was 14 days (range,
7–564 days), and 7 of these patients were neutropenic at the
time of diagnosis. One patient with an adequate neutrophil
count had fusarial endocarditis.
The diagnosis of fusariosis was made at postmortem ex-
amination in 16 (26%) of the patients, and 45 patients received
therapy, including deoxycholate amphotericin B (30 patients),
lipid-based amphotericin B (14 patients), and caspofungin (1
patient). G-CSF and granulocyte-macrophage colony-stimu-
lating factor were provided to 26 patients and 4 patients, re-
spectively. Granulocyte transfusions were used in 13 patients
(including 4 transfusions from donors stimulated with G-CSF).
The median duration of survival after diagnosis was 13 days,
with only 13% of patients remaining alive at 90 days after
diagnosis. The death rates of patients with early, late, and very
late fusariosis were 92%, 72%, and 74%, respectively (Pp
). There was no difference in the death rate according to.12
the type of transplantation (100% for AuSCTs, 83% for MRD
transplants, 89% for MUD transplants, and 83% for MMRD
transplants; ). Univariate predictors of death amongPp .64
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Table 2. Clinical variables of 54 allogeneic hematopoietic stem cell trans-
plant (HSCT) recipients, by time after receipt of transplant.
Variable
Patients receiving diagnosis of fusariosis,
by no. of days after receipt of HSCT
P
0–30
(n p 20)
31–100
(n p 16)
100–365
(n p 10)
1365
(n p 8)
Neutropenia 17 (85) 5 (31) 3 (30) 0 !.0001
Corticosteroid use 12 (60) 12 (75) 5 (50) 3 (38) .31
Acute GVHD 4 (20) 13 (81) NA 2a (25) .004
Chronic GVHD NA 1 (6) 5 (50) 6 (75) !.0001
Disseminated infection 18 (90) 12 (75) 4 (40) 6 (75) .03
NOTE. Data are expressed as no. (%) unless otherwise indicated. GVHD, graft-versus-
host disease; NA, not applicable.
a Indicates receipt of a second HSCT.
Figure 1. Trimodal distribution of cases of fusariosis diagnosed after allogeneic hematopoietic stem cell transplant: early (median, 16 days after
receipt of transplant), late (median, 64 days after receipt of transplant), and very late (median, 508 days after receipt of transplant).
allogeneic HSCT recipients were aGVHD (HR, 2.05; 95% CI,
1.04–4.05; ) and persistent neutropenia (HR, 3.64; 95%Pp .04
CI, 1.29–10.36; ), with persistent neutropenia remainingPp .01
the only significant prognostic factor by multivariate analysis
(HR, 3.65; 95% CI, 1.29–20.36; ).Pp .01
DISCUSSION
Our study is the first to report the clinical characteristics, out-
come, and prognostic factors of fusariosis in HSCT recipients.
Our results indicate that the cumulative incidence of fusariosis
among HSCT recipients varies according to the type of trans-
plantation: lowest among autologous recipients and highest
among the allogeneic MMRD transplant recipients (a 4- and
10-fold higher incidence compared with allogeneic MRD trans-
plant and AuSCT recipients, respectively). This trend is com-
parable to that seen with invasive aspergillosis [7]. We were
surprised to observe a lower incidence of fusariosis among the
MUD HSCT recipients, which may be because of the fact that
patients who received MUD transplants in our series were cared
for at only 1 of the 9 participating centers. A study from this
center had previously reported that fusariosis was more likely
to occur among mismatched or unrelated transplant recipients
than among recipients of a matched related donor product [8].
Of interest, the incidence of fusariosis among HSCT recipients
at this center was lower (5.01 cases per 1000 HSCTs) than that
observed at the other centers (9.11–11.33 per 1000 HSCTs). It
is possible that geographic or other nosocomial factors may
influence the incidence of fusariosis. We also observed that
patients from Brazil and the United States differed in some
aspects. These differences may simply reflect different HSCT
practices among these countries, rather than differences in the
characteristics of fusariosis. In Brazil most centers do not per-
form MUD or MMRD transplantations, and the majority of
transplantations are performed in patients with chronic mye-
loid leukemia.
Aspergillosis after receipt of an allogeneic HSCT has been
reported as having a bimodal distribution (early during neu-
tropenia and a second peak at around day 100 after receipt of
transplant) [9–11], although very late cases of aspergillosis (11
year after receipt of HSCT) do occur [12]. Our results suggest
that, like aspergillosis, fusarial infections have a trimodal dis-
tribution (early, late, and 11 year after receipt of HSCT). Of
note, the second peak of fusariosis occurred 1 month earlier
than that of aspergillosis (median, day 64 vs. day 100, respec-
tively). Our data also suggest that very late (11 year) fusariosis
occurred among patients with adequate neutrophil counts and
who had received MUD or MMRD HSCT and/or were receiving
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Figure 2. Number of cases of fusariosis from 1987 through 1999: all infections (solid squares), fusariosis occurring 30 days after receipt of
transplant (open squares), and fusariosis occurring 130 days after receipt of transplant (solid triangles).
therapy for extensive cGVHD. This population of patients
could be at risk for fusariosis because of the severe T cell—
mediated immunodeficiency, rendering these patients func-
tionally neutropenic [13].
The prognosis of fusariosis among HSCT patients is very
poor, with a median survival of only 13 days after receipt of
transplant, similar to that reported among patients with he-
matological malignancies who did not receive HSCT [3, 14].
As expected, persistent neutropenia was an important prog-
nostic variable [14]. The lack of significance of corticosteroid
therapy as a prognostic factor may be related to the fact that
almost two-thirds of our patients were receiving corticosteroids
at the time of diagnosis, a factor that may have overshadowed
the importance of this variable. GVHD was a significant factor
by univariate analysis but failed to reach statistical significance
by multivariate analysis, probably as a result of the small sample
size of patients with this variable.
In our study, a greater number of cases of fusariosis were
diagnosed in the late 1990s. It is likely that the incidence of
early fusariosis will decline with the more frequent use of non-
myeloablative HSCTs (with shorter duration of neutropenia).
However, the higher incidence and severity of GVHD associated
with nonmyeloablative HSCTs may result in an increased rate
of late fusariosis, as has been reported with aspergillosis [7].
On the other hand, the almost exclusive use of peripheral blood
as a source of autologous stem cells has resulted in a significant
shortening of the duration of neutropenia in this setting, a fact
likely to translate into a marked reduction of fusariosis in this
patient population. Whether the use of CD34 selected grafts,
which is associated with delayed T cell immune reconstitution,
will increase the risk for fusariosis among AuSCT recipients
remains unknown [15].
Of interest, the rate of proven infection in our series (92%)
was significantly higher than that reported with aspergillosis
(∼40%) [10, 16]. This is best explained by the fact that, unlike
Aspergillus species, Fusarium species have a propensity for in-
vading 2 sites (blood and skin) that can be easily sampled for
diagnostic purposes.
Our study suffers from the limitations of all retrospective
studies. Thus, potentially important prognostic variables could
have been missed. Our findings have several clinical implica-
tions. Because patients with very late fusariosis had GVHD and
adequate neutrophil counts, a high index of suspicion for this
infection should be kept in this patient population, regardless
of the number of circulating neutrophils. Given the poor out-
come of fusariosis in HSCT recipients and the relative resistance
of these fungi to antifungal agents, preventive nonchemoth-
erapeutic measures are of paramount importance. Such mea-
sures include a thorough evaluation and treatment of skin le-
sions and tissue breakdown (particularly onychomycoses that
serve as a portal of entry for Fusarium species) before and after
receipt of HSCTs [17] and adequate air and water infection
control practices to avoid environmental exposure to this fun-
gus [18, 19]. Because fusarial infections may recur after im-
munosuppression, judicious use of immunomodulatory agents
after receipt of a HSCT is critical in patients with a history of
fusariosis. Future research should be focused on the evaluation
of strategies derived to reduce the duration of neutropenia (e.g.,
nonmyeloablative regimens, colony-stimulating factors, and
colony-stimulating factors and dexamethasone-elicited WBC
transfusion), as well as the usefulness of new antifungal drugs,
such as voriconazole and posaconazole [20, 21].
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